• About
    • Company Overview
    • Management Team
    • Board of Directors
    • Science Advisors
    • Neurology Advisors
    • Ophthalmology Advisors
    • Contacts
  • Science
    • Publications
    • Collaborators
  • Pipeline
    • Infantile Neuroaxonal Dystrophy (INAD)
    • Friedreich’s Ataxia (FA)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Progressive Supranuclear Palsy (PSP)
    • Dry AMD
    • Future Targets
  • Patient Resources
    • Expanded Access Policy
    • Clinical Trials
    • Additional Resources
  • News & Events
    • Press Releases
    • News
    • Events
    • Videos
  • Careers
HomeSciencePublicationsChapter 31 – Deuterium Protection of Polyunsaturated Fatty Acids against Lipid Peroxidation: A Novel Approach to Mitigating Mitochondrial Neurological Diseases

Chapter 31 – Deuterium Protection of Polyunsaturated Fatty Acids against Lipid Peroxidation: A Novel Approach to Mitigating Mitochondrial Neurological Diseases

Oxidative stress is associated with numerous neurological disorders. Mitochondrial malfunction contributes to generation of reactive oxygen species (ROS) in proximity to mitochondrial membranes rich in polyunsaturated fatty acids (PUFAs). ROS initiate PUFA autoxidation, a chain reaction that alters membrane fluidity and promotes toxic reactive carbonyl products (RCP) that damage proteins and DNA. Due to the stochastic nature of ROS generation, increased antioxidants cannot prevent such injury. However, deuterium-for-hydrogen substitution at bis-allylic sites reduces the rate-limiting step of autoxidation and results in inhibition of the subsequent PUFA oxidation chain reaction, decreasing toxic RCP levels. We propose a novel approach, using such isotopic reinforcement, to alleviate oxidative injury and have pre-clinical evidence demonstrating neuroprotection in an oxidative stress model of Parkinson’s disease. We hypothesize that site-specific PUFA deuteration will mitigate progression of degeneration in other disorders that manifest oxidative injury either as a primary or secondary insult.

Read more…

About
Science
  • Publications
Pipeline
  • Clinical
  • Preclinical
  • Future Targets
Patient Resources
  • Expanded Access Policy
News & Events
Careers
RETROTOPE, 4300 EL CAMINO REAL, SUITE 201, LOS ALTOS, CA 94022
Copyright ©️ 2015-2021 Retrotope Inc.
You are leaving Retrotope’s website. Retrotope does not guarantee the accuracy or completeness of the information contained on any third-party sites, nor does it endorse any of the opinions or information contained on those sites. Please click CONFIRM to continue. CONFIRM